ReviewWorld journal of gastroenterology2022
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia (2023 edition).Hepatology international · 2025Guideline
- The role of platelets in the hepatocellular carcinoma immune microenvironment and their clinical prospects: a comprehensive review.Medical oncology (Northwood, London, England) · 2026Review
- Impact of chronic thrombocytopenia on outcomes after elective lumbar spine fusion: an analysis of the US nationwide inpatient sample.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Efficacy and Safety of Avatrombopag in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Elective Surgery.Journal of clinical medicine · 2026Article
- Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Balancing Thrombosis and Bleeding: Antithrombotic Therapy in Cirrhosis-Related Thrombocytopenia.Journal of clinical medicine · 2026Review
- Impact of chronic thrombocytopenia on clinical outcomes after single-level anterior cervical discectomy and fusion: an analysis of the nationwide inpatient sample of the US.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Coagulation Abnormalities in Liver Cirrhosis: Diagnostic and Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2026Review
- Predictors of 1-month and 3-month readmission among patients with decompensated advanced chronic liver disease admitted at a tertiary hospital in Tanzania: a hospital-based prospective cohort study.BMC gastroenterology · 2026Article
- Prevalence, Risk Factors, Characteristics, and Clinical Outcomes of Thrombocytopenia in the Intensive Care Unit: A Prospective Single-Center Cohort Study.Critical care research and practice · 2026Article
- Thrombocytopenia: from physiological homeostasis imbalance to mechanism-driven precision diagnosis and therapy.Frontiers in immunology · 2026Review
- A Machine Learning-Based Model for Cirrhosis Risk Stratification Incorporating Noninvasive Markers and Clinical Variables.International journal of general medicine · 2026Article
- The Mechanisms behind Thrombocytopenia in Patients with Portal Hypertension and Chronic Liver Disease.Journal of clinical and translational hepatology · 2025Review
- Optimizing perioperative care in liver disease: the role of TPO-receptor agonists.Annals of medicine and surgery (2012) · 2025Article
- Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment.Current oncology (Toronto, Ont.) · 2025Review
- MRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approach.European radiology experimental · 2025Article
- Article
- Colombian consensus on the care of critically ill patients with suspected or confirmed severe yellow fever.Lancet regional health. Americas · 2025Review
- Navigating Severe Thrombocytopenia in End-Stage Liver Disease: A Pre-transplant Management Dilemma.Cureus · 2025Article
- Risk factor analysis and nomogram development for advanced-stage hepatic fibrosis in patients with Wilson's disease.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver disease is characterized by several hematological derangements resulting in a complex and barely rebalanced haemostatic environment. Thrombocytopenia is the most common abnormality observed in these patients and recent advances have led to researchers focus the attention on the multifactorial origin of thrombocytopenia and on the key role of thrombopoietin (TPO) in its physiopathology. Severe thrombocytopenia (platelet count < 50000/μL) complicates the management of patients with chronic liver disease by increasing the potential risk of bleeding for invasive procedures, which may be therefore delayed or canceled even if lifesaving. In the very last years, the development of new drugs which exceed the limits of the current standard of care (platelet transfusions, either immediately before or during the procedure) paves the way to a new scenario in the management of this population of patients. Novel agents, such as the TPO-receptor agonists avatrombopag and lusutrombopag, have been developed in order to increase platelet production as an alternative to platelet transfusions. These agents have demonstrated a good profile in terms of efficacy and safety and will hopefully allow reducing limitations and risks associated with platelet transfusion, without any delay in scheduled interventions. Altogether, it is expected that patients with chronic liver disease will be able to face invasive procedures with one more string in their bow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.